「r1」の検索結果
130件：11～15件目を表示
-
お知らせ | 千寿製薬株式会社
April 6, 2026 Launch of “Avarept® Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition（PDF） December 22, 2025 Obtained manufacturing and marketing approv
http://www.senju.co.jp/english/news/ -
NewMytear CL Cool-s | OTC Products, etc. | Products | SENJU Pharmaceutical
Category 3 OTC medicines New Mytear® CL Cool-s Moisturize with cool sensation while wearing contact lenses CHARACTERISTICS This medicine can be used while wearing all types of contact lenses (hard, so
http://www.senju.co.jp/english/products/clcool-s.html -
Production | About Senju | SENJU Pharmaceutical
Trusted pharmaceutical products are created using the latest and best equipment in the environment with rich humanity. As ophthalmic solutions are required to meet the same quality standards as inject
http://www.senju.co.jp/english/about/production.html -
OTC Products, etc. | Products | SENJU Pharmaceutical
Inquiries are not accepted in a language other than Japanese in principle. Please kindly understand the situation that the inquiries by telephone must use Japanese only. Translated from the Japanese p
http://www.senju.co.jp/english/products/clg.html -
アバレプト懸濁性点眼液0.3%
貯 法：上向き・室温保存 有効期間： 3 年 2025年12月作成 （第 1 版） 2. 禁忌 （次の患者には投与しないこと） 本剤の成分に対し過敏症の既往歴のある患者 ─ 1 ─ 3. 組成・性状 3. 1 組成 3. 2 製剤の性状 4. 効能又は効果 ドライアイ 6. 用法及び用量 通常、1 回 1 滴、1 日 4 回点眼する。 8. 重要な基本的注意 8. 1 本剤の点眼後、一時的に目が
https://www.senju.co.jp/system/files/product_other_file/2026-03/avarept_202512_C3.pdf